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Summary Patients receiving high-dose chemotherapy (HD-CT) are at risk of severe mucositis. Most prevention studies evaluate the degree
of mucositis on clinical, and therefore subjective, measurements. The aim of this study was to develop an objective in vitro assay of
chemotherapy-induced mucositis. Twelve patients with locally advanced breast carcinoma received HD-CT followed by peripheral stem cell
reinfusion. Before and twice weekly after HD-CT, the mucosa was evaluated by an oral washing, a buccal smear and the World Health
Organization (WHO) toxicity grading; furthermore, blood leucocyte levels were determined. For the oral washings, the percentage of viable
epithelial cells was determined by trypan blue dye exclusion and leucocytes were counted by fluorescence microscopy after incubation with
acridine orange. Maturity of buccal cells was assessed by staining buccal smears for morphology according to Papanicolaou (Whitacker D
and Williams V, 1994). Eight healthy volunteers served as controls. The mean percentage (± s.e.m.) of viable oral epithelial cells was stable
in controls (44 ± 2%). In patients, they increased after HD-CT, which was significant after day 7 compared with pretreatment (P < 0.05). In
addition, a shift from mature to immature epithelial cells in buccal smears was observed. Oral leucocyte levels were closely correlated with the
blood leucocyte counts. The WHO score followed the results of these other evaluations with some delay. The viability of buccal cells obtained
by oral washings increases after HD-CT. This is possibly because of desquamation of the upper oral mucosa layer, with a shift from mature to
more immature cells. These data can be quantitated, and this assay may therefore be useful in studies aimed at prevention of mucositis.
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Mucositis is a common, always unpleasant, sometimes unbearable
toxic side-effect of chemotherapy. In particular, in patients
receiving high-dose chemotherapy followed by bone marrow or
peripheral stem cell transplantation, mucositis can be dose
limiting. Chemotherapy causes a direct toxic effect on the rapidly
dividing cells of the basal oral epithelium, which can result in
mucosal atrophy, erythema and ulceration. The severe stages of
mucositis with disruption of the oral mucosal barrier can lead to
mucosal ulcers and secondary infection. In addition, it can provide
a portal ofentry for micro-organisms into the systemic circulation,
which can lead to life-threatening septicaemia in myelosuppressed
patients. Mucositis causes major discomfort, such as pain
requiring intensive analgesia, and may restrict or even prohibit
normal oral feeding and drug intake (Sonis, 1989; Sonis et al,
1990; Toth et al, 1990; Peterson, 1992; Woo et al, 1993).
Grading ofmucositis is necessary to document its degree and to
evaluate the effect of measures for prevention or intervention.
Most available scoring systems are based on a combination of
objective changes in the mucosa (e.g. erythema, ulceration),
subjective complaints (e.g. pain, dryness) and functional impair-
ment (e.g. swallowing, speech) (WHO, 1979; Hickey et al, 1982;
Eilers et al, 1988; Dyck et al, 1991). A major restriction ofmost of
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these scoring systems is the fact that clinically visible mucosal
disorders do not always correlate with complaints by the patient.
Therefore, mucositis can easily be under- or overestimated. In
some scales, local mucositis signs at distinct areas ofthe mouth are
scored separately and subsequently a semi-quantitative score is
obtained (Spijkervet et al, 1989; Schubert et al, 1992).
However, all these scoring systems remain subjective. In
addition, in most scoring systems, the differences between the
succeeding toxicity levels are quite large and, in consequence,
such systems are not ideally suited to the development and recog-
nition ofpreventive methods. Our aim was to develop an objective
in vitro assay for chemotherapy-induced mucositis by measuring
the characteristics of the oral epithelial cells that remain after
chemotherapy.
PATIENTS AND METHODS
Between August 1994 and April 1995, 12 consecutive patients
with locally advanced breast carcinoma with at least four positive
axillary lymph nodes were included. The mean age of the
patients was 44 years (range 24-53 years). After surgery and
induction chemotherapy with four cycles of FEC (5-fluorouracil,
500 mg m-2 intravenously (i.v.); epirubicin, 90 mg m-2 i.v.;
cyclophosphamide, 500 mg m-2 i.v.), patients received high-dose
chemotherapy with carboplatin (1600 mg m-2 i.v.), thiotepa
(480 mg m-2 i.v.) and cyclophosphamide (6 g m-2 i.v.) (CTCb)
divided over days 1-4. This chemotherapy was followed by
peripheral stem cell reinfusion on day 7. Before high-dose
chemotherapy, in all patients, a comprehensive oral and dental
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Figure 1 Mean percentage (± s.e.m.) viable epithelial cells in an oral
washing before and after CTCb
evaluation was performed, including radiographical examination.
All potential risk factors and foci for oral complications during the
neutropenic phase, such as focal periapical or periodontal infec-
tions were eliminated appropriately. During the hours ofhigh-dose
chemotherapy infusion, patients received oral cryotherapy by a
continuous swish around ofice chips inside their mouths. On day 7,
treatment with recombinant granulocyte colony-stimulating factor
(rhG-CSF, Amgen, Thousand Oaks, CA, USA), 300 jg daily
subcutaneously, was started until leucocyte recovery > 3.0 x 109 1-1.
In addition, patients were instructed by the oral hygienist to apply
an oral care regimen, which consisted of frequent sterile saline
rinses together with daily spraying ofthe oral cavity by the nursing
staff. Edentulous patients were instructed not to wear their
dentures after the start of chemotherapy. All patients received
amphotericin-B as oral suspension starting 4 days before CTCb,
intravenously from day 9 after CTCb and lozenges from day 10
after CTCb for prophylaxis of candida infections. In addition, in
cases with positive herpes simplex virus serology, patients
received prophylactic acyclovir 5 mg kg-' t.i.d. i.v., starting day 7.
Moreover, in all patients, oral ciprofloxacin 250 mg b.i.d. was
started 4 days before CTCb for prevention of bacterial infection
and, atday 10, ciprofloxacin was replaced by cotrimoxazole 960-mg
tablets t.i.d. The first four patients received total parenteral nutri-
tion starting on day 4 until they were able to maintain an adequate
oral intake. The succeeding patients only received total parenteral
nutrition when oral intake was insufficient. Before and twice
weekly after chemotherapy, an oral washing as well as a buccal
smear were obtained and mucositis was clinically evaluated by the
WHO toxicity grading. To acquire an oral washing, patients
gargled and rinsed their mouth with 10 ml ofsterile saline for 15 s,
and spat into a tube containing 0.2 ml of fetal calf serum (Gibco,
Paisley, UK). This fluid was centrifuged (190g 10min, room
temperature) and the supernatant was discarded. Sometimes the
oral washing contained many fibres and, in these cases, the fluid
was washed with 30 ml of saline and centrifuged again. Pellets
were resuspended in 1 ml ofRPMI 1640 medium (Gibco, Paisley,
UK) containing 5% fetal calf serum. Subsequently, 50gl of
suspension and 50,l of trypan blue dye (0.4% in 0.15 M sodium
chloride) were combined and immediately transferred to a haemo-
cytometer. Thus, cell counts were performed, after which the
percentage of viable cells and the total cell amounts could be
calculated. In addition, 50gl ofcell suspension was incubated for
15 min with 50gl of acridine orange (1 mg ml-1; Merck,
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Figure 2 Mean leucocyte levels with 95% confidence intervals in blood (V)
and in oral washing (A) before and after CTCb
Darmstadt, Germany) diluted with phosphate-buffered saline
(0.14 M sodium chloride, 2.7 mm potassium chloride, 6.4 mm
disodium hydrogen phosphate, 1.5 mm potassium dihydrogen
phosphate, pH 7.4) to a final concentration of 33 gM) and was
examined by fluorescence microscopy (Olympus IMT). The
percentage of apoptotic cells and the number of leucocytes were
determined. Cells were scored as apoptotic when the nucleus
showed condensation. Leucocytes, in particular neutrophils, could
easily be recognized because oftheir multilobulated nuclei.
On the days that saliva was collected, a smear of the buccal
mucosa was taken and spread on microscope slides. This buccal
smear was stained according to Papanicolaou, which was
followed by assessment of epithelial cell morphology and differ-
entiation/maturation (Whitaker and Williams, 1994). The orange-
coloured, irregularly shaped, sometimes flattened cells were
classified as mature, while the blue/green-coloured, smaller and
rounded cells were categorized as immature cells. Cells with a
partly orange and partly green appearance were graded as interme-
diate cells. On each smear, the percentage of mature, intermediate
and immature cells was determined. Furthermore, on the same
days, blood leucocyte levels were determined. Mucositis was clin-
ically evaluated according to the recommendations of WHO for
grading of toxicity: grade 0, normal with no mucositis; grade 1,
soreness and erythema; grade 2, erythema, ulcers and can eat
solids; grade 3, ulcers and requires liquid diet only; grade 4,
alimentation not possible (WHO, 1979).
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Figure 3 Morphology of buccal epithelial cells stained according to
Papanicolaou. Mean percentage (± s.e.m.) of mature cells (L1), intermediate
(E2) and immature cells (C) before and after CTCb
To establish the assay reproducibility, measurements were
repeated in eight healthy volunteers at least four times in a period
of4 weeks.
Statistical analysis was performed by comparing data using
parametrical and non-parametrical analysis when appropriate and
Spearman's rank correlation. A P-value < 0.05 was considered to
be significant.
RESULTS
In eight healthy volunteers, two men and six women, with a mean
age of 28 years (range 23-33 years) with a healthy oral mucosa
and dentition, a total of 50 oral washings was obtained. The
percentage ofviable oral epithelial cells had a normal distribution,
with a mean of 44% (s.d. 15%). The mean percentage of viable
cells (± s.e.m.) varied between 43% (± 6%) and 47% (± 4%) over
this observation period, and on different days, no significant differ-
ences were found between the mean values. In addition, no differ-
ence was found in the mean percentage of viable cells between
male and female volunteers. The mean total amount of epithelial
cells obtained by an oral washing varied considerably per
individual in various measurements. There were 0.6% (s.d. 1.2%)
apoptotic cells. In oral washings the mean total leucocyte number
was 0.44 ± 0.09 x 109/l-l. The median interval between the fourth
cycle of FEC and high-dose chemotherapy was 35 days (range
21-62 days). During induction chemotherapy, five patients experi-
enced mucositis according to the WHO scoring system: four
patients scored grade I and one patient scored grade II. Onepatient
was edentulous and wore full dentures and three were partly
dentate, whereas the other patients were dentate. Dental screening
for foci ofinfection before high-dose chemotherapy revealed mild
peridontitis in one patient, hyperplastic gingivitis in one patient
and deep pockets with furcation involvement and calculus in
another patient. The remaining patients demonstrated no dental
foci ofinfection. All dental treatment deemed to be necessary was
performed before the start ofhigh-dose chemotherapy. Six patients
received parenteral nutrition besides oral nutrition during treat-
ment; the remaining patients managed to maintain an adequate oral
intake. No differences were observed between patients with or
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Figure 4 Mucositis scores according to the WHO grading system before
and after CTCb
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Figure 5 Percentage of patients with an increased cell viability (2 5%
compared with baseline, *) and an increased WHO mucositis score (A)
during and after CTCb
without parenteral nutrition in respect of the percentage of viable
cells or the clinical mucositis scores.
Figure 1 illustrates the mean percentage ofviable oral epithelial
cells in patients, which gradually rose from 35% ± 7% at baseline
to 67% ± 5% at day 17. After day 7, the increase in viability was
significant compared with pretreatment values (P < 0.05).
Figure 2 shows the pattem of blood leucocyte levels as well as
oral leucocyte levels before and after treatment. Blood leucocytes
decreased to 0.02 x 109 1-' [95% confidence interval (CI)
0.01-0.03 x 1091-] at day 10 (P = 0.0003 compared with baseline)
and increased again between days 14 and 17. The mean leucocyte
level in the oral washing before treatment was 0.25 x 109 1-1
(95% CI 0.12-38.7 x 109 1-1). After an initial increase on day 3
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to 0.50 x 109 1- (95% Cl 0.07-1.10 x 109 1-'; non-significant),
mean leucocyte levels in the oral washing followed the same
pattern as blood leucocyte levels, and a significant correlation was
found (r = 0.94; P = 0.02, Spearman) between leucocyte levels in
blood and the oral washing.
Fluorescence microscopy showed a mean of 1.5% (range
0-10%) apoptotic cells at baseline, which was not significantly
different from the mean percentage of apoptotic cells in healthy
volunteers. After CTCb, no significant changes in the percentage
ofapoptotic cells were found.
The morphology of Pap-stained buccal epithelial cells before
andduring treatment ispresented inFigure 3, showing thatstarting
7 days after CTCb there was a shift from mature to immature
cells. The mean percentage of mature cells before treatment was
37% ± 6%, and this decreased, while on treatment, to 18% ± 5%
on day 17 (P = 0.04, compared with pretreatment). Inversely, the
mean percentage of immature cells increased from 27% ± 5%
before treatment to 49% ± 6% on day 17; this was significant
compared with pretreatment on days 14 and 17 (P = 0.04 and
P = 0.007 respectively).
The mucositis score according to WHO is shown in Figure 4.
Before treatment, and at day 3, none of the patients experienced
mucositis. From this time on, the number of patients with
mucositis increased to a maximum at day 14, when 10 out of 12
patients (83%) had oral complications. Only one patient remained
free ofmucositis, and this patient showed a decreasing percentage
of viable oral epithelial cells after CTCb. Notably, no grade IV
mucositis was observed. On three occasions, the WHO score was
notavailable; onepatient was transferred to the intensive treatment
ward on day 12 because of septicaemia - until that time she had
clinically shown no mucositis and the percentage of viable cells
had increased from 50% to 67%. She was temporarily mechani-
cally ventilated and therefore no measurements wereperformed on
day 14 and 17. One patient was discharged before day 17.
Figure 5 shows that on day 3 none of the patients experienced
mucositisaccording to the WHO score, while in the viability assay
one third ofpatients already showed an increase (> 5% compared
with baseline) in the percentage of viable cells. The WHO score
followed theviability score with some delay.
DISCUSSION
Oral mucositis is a serious complication of treatment with high-
dose chemotherapy because of the considerable distress, pain and
thevulnerability to local as well as systemic infections. Therefore,
many preventive strategies, systemic as well as topical, have been
investigated. Almost all of these studies are evaluated by various
clinical and consequently subjective scoring systems, some
descriptive and some symptom based. Recently, Sonis and
Costello (1995) developed a database for chemotherapy-induced
mucositis and, in the 88 protocols that comprise this database, 14
different scoring systems for mucositis were used. The presence of
such an arsenal of scoring systems suggests that none of them
meets all therequirements of an objective, reliable scoring system.
Some difficulties in these systems are their reproducibility, the
large inter-system differences between the toxicity levels and the
low sensitivity of most systems.
In the presentstudy, we made an attempt to develop an objective
in vitro assay forquantitation ofchemotherapy-induced mucositis.
In healthy volunteers, the percentage of viable oral epithelial
cells followed a normal distribution with a mean of 44%o of total
epithelial cells. In patients, the percentage ofviable cells as well as
the percentage of oral leucocytes before treatment were low
compared with healthy volunteers. The reason for this is not clear;
it is possible that differences in age have contributed as the
mucosal turnover is decreased in older patients and the mitotic
index is higher in younger patients (Lockhart and Sonis, 1979;
Sonis, 1989). Prior induction chemotherapy could be another
factor. During and after treatment, we observed an increasing
percentage of viable oral epithelial cells. In addition, in the buccal
smears, the percentage ofmature cells decreased while an increase
in the percentage ofimmature cells was observed. This isprobably
due to an increased desquamation ofthe upper oral epithelial layer
after high-dose chemotherapy. Possibly, the immature cells are
more viable than mature cells and therefore the increased
percentage of viable oral epithelial cells after treatment may be
explained by the increased percentage of immature cells after
treatment.
The nadir in blood leucocyte levels between day 10 and 14
coincided with the leucocyte nadir in the mouth rinse. This is in
accordance with the previous studies ofWright et al (1986). They
observed in patients recovering from a profound neutropenia
because of chemotherapy without haematological growth factors
that neutrophils reappeared and returned to a stable level earlier in
the oral mucosa than in the blood. In the present study, a correla-
tion between leucocyte levels in oral washings and in blood is
obtained. From our twice-weekly sampling, nojudgement can be
given as to whether leucocytes reappear earlier in the oral washing
than in the blood. Lieschke et al (1992) found that neutrophil
levels in oral washings after chemotherapy followed by autolo-
gous bone marrow transplantation recovered earlier than those in
blood, especially when patients used G-CSF. In addition, in
patients receiving G-CSF, the mean mucositis score was reduced
compared with patients without supportive care with G-CSF. This
phenomenon has also been observed by Gabrilove et al (1988) in a
randomized study evaluating the effect of G-CSF on neutropenia
and associated morbidity. It was suggested that the neutrophils
exposed to the G-CSF were still able to leave the circulation and
serve in host defence in mucosal tissue and this is possibly the
reason for the reduced incidence of mucositis observed in the
G-CSF-treated patients (Lieschke et al, 1992). GM-CSF is also
known to be effective in reducing the duration and the severity of
chemotherapy-induced oral mucositis (Chi et al, 1995).
The percentage of apoptotic cells in healthy volunteers was
0.5% ± 0.2% and in patients the pretreatment value tended to be
higher, 1.5% ± 1% (non-significant), without a significant change
after treatment. Birchall et al (1995) observed in six biopsies of
normal buccal epithelium an apoptotic index of 0.12 ± 0.07. The
apparent difference between biopsy and washing could be
explained by the selection ofnon-viable cells by washing. In addi-
tion, in future studies, the evaluation of oral epithelial apoptotic
cell numbers can be extended with other assay systems.
Clinical evaluation ofmucositis with the WHO criteria revealed
no grade IV toxicity, and only one-third of patients experienced
grade III toxicity. Previously, a correlation between the severity of
mucositis and the degree of neutropenia has been observed
(Lockhart and Sonis, 1979; Kenny, 1990). Furthermore, treatment
with G-CSF, which is known to be effective in reducing the
severity of and shortening the duration of standard or high-dose
chemotherapy (Gabrilove et al, 1988; Sheridan et al, 1989), may
be beneficial in the prevention ofsevere mucositis. In addition, the
use of peripheral stem cells is associated with a shortened period
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of low neutrophil count compared with autologous bone marrow
(Schmitz et al, 1996), and consequently this also could have
influenced the severity ofmucositis.
The change in viability preceded the change in WHO score.
This means that this assay is more sensitive for the detection of
mucositis than the WHO toxicity grading system.
The increased sensitivity of this new, simple assay can be
beneficial in studies aimed at mucositis prevention in the future,
because this increased sensitivity probably identifies small differ-
ences not previously detectable. In our opinion, future prevention
studies will focus on several cytokines and scavengers, parenter-
ally as well as locally applied. An example is the topical applica-
tion ofTGF-fB1, which reduced incidence, severity and duration of
oral chemotherapy-induced mucositis in Syrian gold hamsters
(Sonis et al, 1994).
In conclusion, after high-dose chemotherapy, the percentage of
viable oral epithelial cells increases. Also, a shift from mature to
immature cells in the buccal epithelium is observed. This is
possibly due to a desquamation of the upper oral epithelial layer.
Counting the percentage ofviable oral epithelial cells in oral wash-
ings is therefore a new, objective in vitro assay for chemotherapy-
induced mucositis and may be more sensitive than the WHO
scoring system. It may also be useful as an objective parameter in
studies focused on mucositis prevention.
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